Skip to content

Research on the therapeutic effect and safety of electropuncture on metabolic syndrome due to olanzapine and risperidone

Research on the therapeutic effect and safety of electropuncture on metabolic syndrome due to olanzapine and risperidone

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800016687
Enrollment
Unknown
Registered
2018-01-20
Start date
2017-12-20
Completion date
Unknown
Last updated
2018-06-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Capital Medical University

Interventions

control group:shame electropuncture

Sponsors

Beijing Anding Hospital affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Hospitalized or outpatient patients diagnosed with schizophrenia according to the International Classification of Diseases (ICD-10); 2. Taking olanzapine and risperidone more than one month; 3. Metabolic syndrome by the global consensus of International Diabetes Federation (2015); 4. Aged between 18 and 60 years male or female; 5. The patients or their legal guardian sign an informed consent.

Exclusion criteria

Exclusion criteria: 1. Diagnoses of severe cardiac, cerebral, renal or hepatic disease; 2. Metabolic syndrome caused by other reasons except antipsychotic drugs; 3. Women who are breastfeeding, pregnant or may be pregnant during the trial; 4. An intolerant of electroacupuncture, or history of syncope; 5. Difficult to complete the inspection and treatment.

Design outcomes

Primary

MeasureTime frame
BMI;weight;

Secondary

MeasureTime frame
Blood pressure;blood lipid;fasting glucose;

Countries

China

Contacts

Public ContactDongqing Yin

Beijing Anding Hospital affiliated to Capital Medical University

yindq1123@163.com+86 13811005469

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026